pharmaranks analyzed 1,649 FDA drug recalls from Jan 2, 2024 to Jun 12, 2026.Here is what the data shows — how serious the recalls were, why drugs got pulled, and who recalled the most. All figures are computed directly from the U.S. FDA’s openFDA Enforcement database; nothing is estimated.
By recall initiation date. Recalls rose 40% from 2024 to 2025. The current year is partial (data through Jun 12, 2026).
The FDA grades every recall by risk. Class I is the most dangerous — a reasonable probability of serious harm or death.
May cause temporary or medically reversible harm; low probability of serious harm.
Unlikely to cause harm but violates FDA labeling or manufacturing regulations.
Most serious — a reasonable probability that use will cause serious harm or death.
Recall reasons, grouped from the FDA’s free-text reason field. "Manufacturing (CGMP) deviations" led with 517. Manufacturing and contamination problems alone account for 846 (51%).
Companies with the most recall events in the period (largely generic-drug makers). A high count reflects recall volume, not necessarily overall quality — large generics portfolios recall more.
Recent Class I recalls — the FDA’s highest-risk tier.
All figures are computed directly from the U.S. FDA’s openFDA drug Enforcement database (1,649 recall records initiated Jan 2, 2024–Jun 12, 2026, covering 350 manufacturers across 41states). Recall reasons are grouped by keyword from the FDA’s free-text field, so categories are approximate; counts by class, year, firm, and status are exact. Many recalls are still “ongoing,” so totals for recent periods will rise. Updated hourly from our live drug recall tracker.
Cite this report:“FDA Drug Recall Report,” pharmaranks, Jun 12, 2026. https://pharmaranks.com/recalls/report